Carcinoma, Pancreatic Ductal Clinical Trial
Official title:
Comprehensive Molecular Characterization of Advanced Pancreatic Ductal Adenocarcinomas (PDAC) for Better Treatment Selection: A Prospective Study
Researchers are looking for better ways of understanding and treating pancreatic cancer. The purpose of this study is to see how useful it is to look for changes and characteristics in your genes (molecules that contain instructions for the development and functioning of the cells) and the genes within the tumour. These characteristics may be useful in choosing treatments for patients in the future. Changes (mutations) in genes have been shown to be an important characteristic in cancers. Looking at differences in genes in patients with advanced pancreatic ductal adenocarcinomas and comparing this information with response to their initial chemotherapy treatment may help to learn which treatments may be better for certain patients after initial treatment.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03500068 -
Establishing Organoids From Metastatic Pancreatic Cancer Patients, the OPT-I Study.
|
N/A | |
Not yet recruiting |
NCT05489458 -
Predictive Factors for Resection and Survival in Type A Borderline Resectable Pancreatic Ductal Adenocarcinoma Patients After Neoadjuvant Therapy
|
||
Recruiting |
NCT02310230 -
An Evaluation of the Utility of the ExSpiron Respiratory Variation Monitor During Upper GI Endoscopy
|
N/A | |
Completed |
NCT01478685 -
A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors
|
Phase 1 | |
Completed |
NCT03513705 -
Impact of Nationwide Enhanced Implementation of Best Practices in Pancreatic Cancer Care (PACAP-1)
|
N/A | |
Completed |
NCT01808638 -
Atu027 Plus Gemcitabine in Advanced or Metastatic Pancreatic Cancer (Atu027-I-02)
|
Phase 1/Phase 2 | |
Withdrawn |
NCT00226746 -
Efficacy Study of Gemcitabine, Paclitaxel, and Irradiation in the Treatment of Pancreatic Cancer
|
Phase 2 | |
Not yet recruiting |
NCT03432624 -
Detection of MicroRNA-25 in the Diagnosis of Pancreatic Cancer
|
N/A | |
Recruiting |
NCT02451384 -
According CTC to Compare the Influences of Different Methods to Remove the PDAC
|
N/A | |
Recruiting |
NCT02529579 -
Safety and Efficacy Evaluation of iAPA-DC/CTL Combined Gemcitabine Therapy on Advanced Pancreatic Cancer
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06447662 -
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
|
Phase 1 | |
Recruiting |
NCT02817308 -
Correlation of Serum CA19-9 Levels With Levels in Saliva and Urine of Patients With Ductal Adenocarcinoma of the Pancreas
|
N/A | |
Completed |
NCT00471146 -
Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer.
|
Phase 3 | |
Recruiting |
NCT05461430 -
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
|
||
Terminated |
NCT01413451 -
Amatuximab for High Mesothelin Cancers
|
Early Phase 1 | |
Recruiting |
NCT03403101 -
The Combination Chemotherapy of SIRIOX as First- or Second-Line Chemotherapy for Pancreatic Cancer
|
Phase 2 | |
Recruiting |
NCT02928081 -
Standard Versus Extended Lymphadenectomy in Pancreatoduodenectomy for Patients With Pancreatic Head Adenocarcinoma
|
N/A | |
Completed |
NCT05723978 -
Selective Extended Dissection in Different Types of Pancreatic Head Cancer: A Retrospective Cohort Study.
|
||
Completed |
NCT02150746 -
Circulating Tumor Cells in Operative Blood
|
N/A | |
Completed |
NCT04146441 -
Ultrasound-enhanced Uptake of Chemotherapy in Patients With Inoperable Pancreatic Ductal Adenocarcinoma
|
Phase 2 |